The EPS miss is material, but the pending BSX acquisition at a premium likely provides a floor. Monitor for regulatory updates on the deal close; any delay or termination risk would expose the stock to the full EPS miss. The lack of guidance removes a typical catalyst, making the stock a binary bet on deal completion.
Price Chart
Executive Summary
Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY), in line with consensus, but EPS of $0.88 (diluted) missed the $1.18 consensus estimate by 25.4%. The company is not providing guidance due to the pending acquisition by Boston Scientific (BSX), which introduces deal-closing risk and removes the typical earnings catalyst. The EPS miss is significant, but the acquisition premium likely caps downside.
Key Financial Metrics
Key Facts
- Revenue of $390.0M, +14.9% YoY, in line with $390.1M consensus
- Diluted EPS of $0.88, missed consensus of $1.18 by 25.4%
- Net income of $34.8M, down from $45.3M in Q2 2025
- Global thrombectomy revenue $259.0M (+12.5% YoY); embolization & access $131.1M (+20.0% YoY)
- Gross margin improved 190bps to 67.9%
- Operating expenses rose 22.2% YoY, including $6.9M in acquisition-related costs
- No FY2026 guidance provided due to pending Boston Scientific acquisition
- Cash & investments of $658.8M as of June 30, 2026
Financial Impact
EPS miss of $0.30 vs consensus; revenue in line; net income down 23% YoY
Risk Factors
- Pending Boston Scientific acquisition may not close on expected timeline or at all
- EPS miss signals potential operational or margin pressure beyond acquisition costs
- No guidance removes forward visibility, increasing uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302838410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | Press Release | $321.19 $321.68 | ▼ −0.15% | ▲ +2.84% | $317.55 (+1.13%) |
May 7, 2026 21w ago | 425 | $324.65 $319.37 | ▼ −1.63% | ▼ −4.76% | $317.55 (−2.19%) |
May 6, 2026 21w ago | 8-K | $324.65 $319.37 | ▲ +1.63% | ▲ +4.76% | $317.55 (+2.19%) |
Apr 29, 2026 22w ago | DEFA14A | $326.48 $318.30 | ▼ −2.51% | ▼ −7.73% | $317.55 (−2.74%) |
Apr 17, 2026 24w ago | 425 | $329.71 $326.54 | ▼ −0.96% | ▼ −5.16% | $317.55 (−3.69%) |
Apr 1, 2026 26w ago | DEFM14A | $330.36 $326.48 | ▼ −1.17% | ▼ −11.05% | $317.55 (−3.88%) |
Feb 25, 2026 31w ago | 8-K | $338.67 $336.27 | ▼ −0.71% | ▲ +4.53% | $317.55 (−6.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access